SEMA3A and schizophrenia: Sema3A has been implicated in neuropsychiatric diseases such as schizophrenia (Gilabert-Juan et al., 2015), Alzheimer’s disease (AD; Wang et al., 2021) and epilepsy (Van Battum et al., 2015), and its accumulation in hippocampal neurons induces programmed cell death, which is shown to contribute to AD development (Good et al., 2004).